|
Kloos et al., 2009
|
Total 56 (44.6%): Treatment group 19 (42%); Control group 37 (45.9%)
|
-
|
Papillary (73%), Follicular (4%), Hurthle cell (16%), Anaplastic (7%)
|
BM (21%)
|
Evaluate the activity of sorafenib in metastatic thyroid carcinoma
|
Treatment group; sorafenib 400 mg PO bd
|
Lung (96), lymph (94%), other (14%)
|
Partial response in 15% of patients (7.5 months median duration). Median progression-free survival was 15 months
|
|
Cabanillas et al., 2010
|
15 (60%)
|
61 (38–83)
|
PWD (53.3%), FWD (33.3%), Hurthle (13.3%)
|
BM (26.7%)
|
Evaluate the activity of sorafenib and sunitinib in progressive and radioactive resistant DTC
|
Sorafenib 200–400 mg PO bd 86.7%, sunitinib 50 mg PO od 13.3%
|
Lymph (73.3%), lung (66.7%), pleura (13.3%)
|
SD 9 (60%), PR 3 (20%), PD 3 (20%). 2 yr survival 67%
|
|
Orita et al., 2011
|
Total 50 (72%): Treatment group 22 (68.2%); Control 28 (75%)
|
59 (32–77)
|
PWD (52%), FWD (48%)
|
SM (40%), BM (100%)
|
Evaluate the efficacy of ZA for treatment of symptomatic BM in DTC
|
Treatment group; ZA 4 mg IV/month (100%), Surgery (18%), ERT (77%), RAI (50%)
|
Others (60%)
|
Treatment group/control SRE-free 3 yr survival: 86%/50%, mortality 54%
|
|
Wells et al., 2012
|
Total 331 (42.6%): Treatment group 231 (42%); Control group 100 (44%)
|
-
|
Advanced MTC (100%)
|
Treatment group BM (34%), control group BM (40%)
|
Evaluate the efficacy of vandetanib in advanced or metastatic MTC
|
Treatment group; vandetanib 300 mg PO
|
Hepatic (46.5%), lymph nodes (40.8%), respiratory (38.1%), neck (10.0%)
|
Significant prolongation of PFS with vandetanib compared with placebo. PD 37%, mortality 15%
|
